Welcome to our dedicated page for Airsculpt Technologies SEC filings (Ticker: AIRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AirSculpt Technologies, Inc. filings document the regulatory record of a public medical aesthetics company that provides premium body contouring procedures. Its 8-K reports cover operating and financial results, preliminary updates, non-GAAP financial measures, reconciliations, debt and capital-structure disclosures, material agreements, and governance events.
Proxy materials describe annual meeting matters, director elections, shareholder voting items, board structure, and related governance disclosures. Other filings include late-filing notices tied to annual report timing, amendments correcting non-GAAP presentation, and emerging growth company status under SEC reporting rules.
AirSculpt Technologies, Inc. CEO Yogesh Jashnani reported a tax-related share withholding tied to restricted stock vesting. On February 3, 2026, 55,098 shares of common stock vested from restricted stock units. The company withheld 24,217 shares, valued at $2.58 per share, to cover $62,484.48 of withholding taxes. After this transaction, Jashnani directly beneficially owned 496,759 shares of AirSculpt Technologies common stock.
Airsculpt Technologies, Inc. received an updated ownership report showing that individual investor Jorey Chernett beneficially owns 6,156,061 shares of its common stock, representing 9.86% of the outstanding class.
Chernett reports sole voting and dispositive power over all these shares and certifies they were not acquired to change or influence control of Airsculpt. The ownership level triggered this amended Schedule 13G filing based on an event dated January 30, 2026.
AirSculpt Technologies' Chief Financial Officer received new equity awards tied to service and performance. On January 24, 2026, the CFO was granted 147,059 restricted stock units (RSUs) and 147,059 performance stock units (PSUs) at a price of $0 per unit.
The RSUs vest in three equal annual installments starting January 24, 2027, contingent on continued employment. Each PSU represents a right to one share of common stock and will vest based on relative total shareholder return over a three-year period compared with the S&P Health Care Select Industry Index, with outcomes ranging from 0% to 200% of the target award.
Jorey Chernett has filed a Schedule 13G reporting a significant passive stake in Airsculpt Technologies, Inc. He reports beneficial ownership of 3,188,767 shares of Airsculpt common stock, representing 5.11% of the outstanding class as of the filing date. Chernett has sole power to vote and to dispose of all 3,188,767 shares, with no shared voting or dispositive power disclosed.
He certifies that the shares were not acquired and are not held for the purpose of changing or influencing control of Airsculpt, but instead are held on a passive basis consistent with Schedule 13G requirements.
Airsculpt Technologies, Inc. Chief Financial Officer Arthur Michael J filed an initial insider ownership report on Form 3. The filing states that no securities of Airsculpt Technologies, Inc. are beneficially owned, as noted in the remarks that no securities are beneficially owned and supported by empty ownership tables for both non-derivative and derivative securities.
Airsculpt Technologies, Inc. (AIRS) disclosed an initial statement of beneficial ownership by a director on Form 3. The reporting person is identified as a director of the company and files individually rather than as part of a group. As of the event date of 11/14/2025, the director reports beneficial ownership of 375,934 shares of Airsculpt Technologies common stock, $0.001 par value, held in direct form. The filing shows no derivative securities currently reported in Table II and includes a power of attorney authorizing an attorney-in-fact to sign on the reporting person's behalf.
AirSculpt Technologies, Inc. appointed Michael Doyle as a Class III director and the Non-Executive Chairman of the Board, effective November 14, 2025. He will stand for election by stockholders at the company’s 2027 annual meeting. Doyle is an experienced healthcare services executive, currently Managing Partner of Vesey Street Capital Partners and formerly CEO of Surgery Partners, where he led the business for about 15 years and expanded it from 3 to over 175 locations. He has also chaired several physician and dental organizations and previously served on the board of managers of Elite Body Sculpture, the company’s predecessor before its IPO. The board determined that he qualifies as an independent director under Nasdaq rules, and he will not receive compensation for serving as a director and Non-Executive Chairman. The company also filed a press release as an exhibit to this report.
AirSculpt Technologies (AIRS) reported weaker Q3 2025 results. Revenue was $34.99 million, down about 18% year over year as procedure volumes and demand across the aesthetics industry softened. The company posted a net loss of $9.51 million (basic and diluted loss per share of $0.15) versus a $6.04 million loss a year ago.
Results included non-cash charges: a $4.6 million impairment tied to portions of a Salesforce implementation and a $2.3 million impairment from the planned closure of the London facility. Management also accelerated $1.0 million of rent expense related to ceasing use of the London lease on November 15, 2025. Same-center cases fell 20.5% with revenue per case modestly lower.
Cash was $5.41 million at quarter-end, and term debt (net) was $56.91 million at an 8.82% interest rate. During Q2, AirSculpt raised approximately $13.8 million net in an underwritten offering and prepaid $10.0 million on the term loan, while amending covenants to provide near-term flexibility. Management is executing cost reductions estimated at $3.0 million annually and has paused new center openings.
AirSculpt Technologies announced quarterly results and updated 2025 revenue guidance and Adjusted EBITDA guidance via press release, and named Michael Arthur as Chief Financial Officer, effective January 5, 2026.
Arthur’s compensation includes a $400,000 annual base salary, target cash bonus equal to 50% of salary (from fiscal 2026), a $100,000 sign‑on cash bonus, and a $600,000 sign‑on equity grant split between RSUs ($300,000) and PSUs ($300,000). RSUs vest over three years; PSUs vest over three years based on relative total shareholder return with achievement from 0% to 200%. Severance provides nine months’ salary and COBRA contributions, or upon a change in control, a lump sum of salary plus target bonus, 12 months’ COBRA contributions, full RSU acceleration, and PSU conversion as described.
AirSculpt Technologies (AIRS) announced a leadership change. On November 4, 2025, Dr. Aaron Rollins resigned as executive chairman and as a member of the board of directors, effective the same day.
The company stated that Dr. Rollins’ resignation was not due to any disagreements with the company, its management, or the board on matters related to operations, policies, or practices. The filing lists no additional board or management changes or interim appointments.